Almirall S.A.
Global biopharmaceutical company specializing in medical dermatology and skin health.
ALM | MC
Overview
Corporate Details
- ISIN(s):
- ES0157097017
- LEI:
- 95980020140005007996
- Country:
- Spain
- Address:
- Ronda General Mitre 151, 08022 Barcelona
- Website:
- http://www.almirall.com
- Sector:
- Manufacturing
Description
Almirall S.A. is a global biopharmaceutical company specializing in medical dermatology. The company focuses on the research, development, manufacturing, and commercialization of proprietary medicines to address significant unmet needs in skin health. Leveraging scientific innovation, Almirall provides medical solutions designed to improve the well-being and quality of life for patients. Its operations encompass in-house research and development, strategic partnerships, and in-licensing to expand its portfolio of dermatological treatments.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-02-24 06:27 |
Encuentro con analistas e inversores institucionales: Presentación de Resultado…
|
Spanish | 102.8 KB | ||
| 2025-02-24 00:00 | English | 1.7 MB | |||
| 2025-02-24 00:00 | English | 5.8 MB | |||
| 2025-02-24 00:00 | Spanish | 17.9 MB | |||
| 2025-01-31 07:57 |
Almirall desinvierte Algidol® y licencia Sekisan®
|
Spanish | 68.0 KB | ||
| 2025-01-20 12:11 |
Operaciones del contrato de liquidez durante el cuarto trimestre de 2024
|
English | 184.8 KB | ||
| 2025-01-13 17:31 |
Presentación: J.P. Morgan Healthcare Conference 2025
|
English | 1.7 MB | ||
| 2024-10-15 15:22 |
Operaciones del contrato de liquidez durante el tercer trimestre de 2024
|
English | 567.8 KB | ||
| 2024-09-25 12:45 |
EBGLYSS® (lebrikizumab): resultados ADjoin 3 años
|
Spanish | 125.9 KB | ||
| 2024-07-22 06:59 |
Almirall remite presentación sobre los Resultados del primer semestre de 2024
|
Spanish | 1.7 MB | ||
| 2024-07-16 18:17 |
Operaciones del contrato de liquidez durante el segundo trimestre de 2024
|
Spanish | 193.3 KB | ||
| 2024-06-12 08:27 |
Información sobre dividendos
|
Spanish | 84.2 KB | ||
| 2024-06-10 08:04 |
La FDA de EEUU aprueba la extensión de tratamiento de Klisyri® (tirbanibulina) …
|
Spanish | 105.0 KB | ||
| 2024-06-05 17:38 |
Información sobre dividendo
|
Spanish | 94.4 KB | ||
| 2024-05-13 07:03 |
Almirall remite presentación sobre los Resultados del primer trimestre de 2024
|
Spanish | 1.7 MB |
Automate Your Workflow. Get a real-time feed of all Almirall S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Almirall S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Almirall S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
